USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: TANOX, INC.
City: HOUSTON
State: TX
Zip+4: 77025
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: (713) 664-2288

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $410,846.00 7
SBIR Phase II $985,449.00 2

Award List:

ANTI-IDIOTYPIC VACCINES FOR AIDS

Award Year / Program / Phase: 1988 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $45,000.00

CHIMERIC CD4/IMMUNOGLOBULIN ANTIBODIES FOR AIDS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $44,192.00
Abstract:
One of the most urgent challenges facing the medical community is the development of effective therapeutic agentsfor victims of the worldwide aids epidemic. because of their high degree of specificity and highly specialized effector functions, monoclonal anti-hiv envelope protein antibodies are… More

IMMUNOTOXIN THERAPY FOR AIDS

Award Year / Program / Phase: 1989 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $46,770.00

ANTI-IDIOTYPIC VACCINES FOR AIDS

Award Year / Program / Phase: 1990 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $500,000.00
Abstract:
The geometric increase in the number of individuals infected by human immunodeficiency virus type 1 (hiv-1) has created serious social, economical and life-threatening issues to the human race. it is of pressing concerns to develop effective measures for controlling the spread of this disease,… More

EXPRESSION OF AN ANTI-IDIOTYPIC FV FRAGMENT AS A VACCINE FOR AIDS

Award Year / Program / Phase: 1990 / SBIR / Phase I
Agency: HHS
Principal Investigator: Lee K Sun
Award Amount: $49,884.00
Abstract:
Tanox biosystems, inc., has generated an anti-idiotype (id) monoclonal antibody (mab), ab19-4, to the hiv-1-neutralizing mab, bat123, which recognizes an immunodominant region of gp120. research has characterized ab19-4 to be a paratope-specific anti-id mab that mimics the three-dimensional… More

IMMUNOTOXIN THERAPY FOR AIDS

Award Year / Program / Phase: 1991 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $485,449.00
Abstract:
The geometric increase in the number of individuals infected by human immunodeficiency virus type 1 (hiv-1) has created serious social, economic, and life-threatening issues for the human race. it is of pressing concern to develop effective measures for controlling the spread of this disease. this… More

ENHANCEMENT OF MUCOSAL IMMUNITY

Award Year / Program / Phase: 1992 / SBIR / Phase I
Agency: HHS
Principal Investigator: Cheng Peng
Award Amount: $50,000.00
Abstract:
The rate of heterosexual transmission of hiv-1 through sexual contacts is increasing in most countries. like many other pathogenic microorganisms, hiv-1 virions enter the body through mucosal surface of genital tracts. however, it has been suggested in the rhesus marcaque/siv model that the vaccines… More

Broad Cross-Reactivity of HIV-1 Neutralizing Antibody

Award Year / Program / Phase: 1994 / SBIR / Phase I
Agency: HHS
Principal Investigator: Joseph Major
Award Amount: $75,000.00
Abstract:
Passive immunization with broadly neutralizing antibodies is a promising approach for preventionand treatment of HIV-1 infection. We have generated an HIV-1 neutralizing human antibody which bindsto the principal neutralizing determinant (PND) of the envelope glycoprotein gp12O. The antibody… More

N/A

Award Year / Program / Phase: 2000 / SBIR / Phase I
Agency: HHS
Principal Investigator: Michael S. Fung
Award Amount: $100,000.00